BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 22339554)

  • 1. Recent trends in cancer drug resistance reversal strategies using nanoparticles.
    Palakurthi S; Yellepeddi VK; Vangara KK
    Expert Opin Drug Deliv; 2012 Mar; 9(3):287-301. PubMed ID: 22339554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives.
    Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
    Curr Pharm Des; 2017; 23(22):3301-3308. PubMed ID: 28403792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer stem cell-targeted therapeutics and delivery strategies.
    Ahmad G; Amiji MM
    Expert Opin Drug Deliv; 2017 Aug; 14(8):997-1008. PubMed ID: 27866420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoways to overcome docetaxel resistance in prostate cancer.
    Ganju A; Yallapu MM; Khan S; Behrman SW; Chauhan SC; Jaggi M
    Drug Resist Updat; 2014 Apr; 17(1-2):13-23. PubMed ID: 24853766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
    Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
    J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicine to overcome cancer multidrug resistance.
    Yang X; Yi C; Luo N; Gong C
    Curr Drug Metab; 2014; 15(6):632-49. PubMed ID: 25255871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach.
    Malhi S; Gu X
    Expert Opin Drug Deliv; 2015 Jul; 12(7):1177-201. PubMed ID: 25601619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in drug delivery strategies for treatment of ovarian cancer.
    Zahedi P; Yoganathan R; Piquette-Miller M; Allen C
    Expert Opin Drug Deliv; 2012 May; 9(5):567-83. PubMed ID: 22452661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can nanomedicines kill cancer stem cells?
    Zhao Y; Alakhova DY; Kabanov AV
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1763-83. PubMed ID: 24120657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nano-based strategies to overcome p-glycoprotein-mediated drug resistance.
    Niazi M; Zakeri-Milani P; Najafi Hajivar S; Soleymani Goloujeh M; Ghobakhlou N; Shahbazi Mojarrad J; Valizadeh H
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1021-33. PubMed ID: 27267126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. siRNA-Conjugated Nanoparticles to Treat Ovarian Cancer.
    Halbur C; Choudhury N; Chen M; Kim JH; Chung EJ
    SLAS Technol; 2019 Apr; 24(2):137-150. PubMed ID: 30616494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells.
    McIntosh K; Balch C; Tiwari AK
    Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):633-44. PubMed ID: 27116192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.
    Milane L; Ganesh S; Shah S; Duan ZF; Amiji M
    J Control Release; 2011 Oct; 155(2):237-47. PubMed ID: 21497176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
    Kibria G; Hatakeyama H; Harashima H
    Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer.
    Pan ZZ; Wang HY; Zhang M; Lin TT; Zhang WY; Zhao PF; Tang YS; Xiong Y; Zeng YE; Huang YZ
    Acta Pharmacol Sin; 2016 Aug; 37(8):1110-20. PubMed ID: 27292613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells.
    Barrera G; Daga M; Ferrara B; Dianzani C; Pizzimenti S; Argenziano M; Cavalli R; Trotta F
    Curr Med Chem; 2017; 24(42):4800-4815. PubMed ID: 27919217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells.
    Gao J; Li W; Guo Y; Feng SS
    Nanomedicine (Lond); 2016 Dec; 11(24):3261-3282. PubMed ID: 27854161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.